In NMA, we comprehensively compared the efficacy of multiple first-line treatments, including all available EGFR-TKIs, cytotoxic agents, and combination strategies for advanced NSCLC patients harboring two different common EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.